Status:
COMPLETED
Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
This study is conducted in Asia, Europe, Japan and North America. The aim of this observational study is to evaluate the safety and effectiveness while using NovoMix® 30 during 26 weeks under normal c...
Eligibility Criteria
Inclusion
- Age according to approved label and physician discretion
- Type 2 diabetes including newly-diagnosed subjects who have never received insulin or an insulin analogue before
Exclusion
- Subjects who previously enrolled in this study
- Subjects who are unlikely to comply with protocol requirements
- Hypersensitivity to biphasic insulin aspart or to any of the excipients
- Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months
Key Trial Info
Start Date :
September 11 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 15 2008
Estimated Enrollment :
57610 Patients enrolled
Trial Details
Trial ID
NCT00659282
Start Date
September 11 2006
End Date
November 15 2008
Last Update
January 12 2018
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Mississauga, Canada, L4W 4XI
2
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China, 100004
3
Novo Nordisk Investigational Site
Vouliagment, Greece, 16671
4
Novo Nordisk Investigational Site
Bangalore, India, 560001